Last reviewed · How we verify

propofol, rocuronium and fentanyl

Al-Azhar University · FDA-approved active Small molecule

This is a combination of three anesthetic and neuromuscular agents: propofol (GABA agonist for sedation), rocuronium (neuromuscular blocker), and fentanyl (opioid analgesic) used together for anesthesia induction and maintenance.

This is a combination of three anesthetic and neuromuscular agents: propofol (GABA agonist for sedation), rocuronium (neuromuscular blocker), and fentanyl (opioid analgesic) used together for anesthesia induction and maintenance. Used for Induction and maintenance of general anesthesia for surgical procedures, Sedation in intensive care units.

At a glance

Generic namepropofol, rocuronium and fentanyl
SponsorAl-Azhar University
Drug classAnesthetic combination (intravenous anesthetic, neuromuscular blocking agent, opioid analgesic)
TargetGABA-A receptor (propofol); nicotinic acetylcholine receptor at neuromuscular junction (rocuronium); mu-opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Propofol enhances inhibitory GABA signaling in the central nervous system to produce rapid sedation and hypnosis. Rocuronium competitively blocks acetylcholine at the neuromuscular junction to provide skeletal muscle paralysis. Fentanyl is a potent mu-opioid receptor agonist that provides analgesia and contributes to sedation. Together, these agents are used as a balanced anesthetic regimen for surgical procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: